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Introduction
Small molecule CCR5 inhibitors represent a new class of drugs for treating human immunodeficiency virus type 1 (HIV-1) infection. These molecules bind to a hydrophobic cavity located between the transmembrane domains of CCR5 and inhibit HIV-1 entry allosterically; i.e., by inducing conformational changes in CCR5 (Dragic et al., 2000; Tsamis et al., 2003) . For HIV-1 to enter target cells, the gp120 subunit of the viral envelope glycoprotein (Env) associates with the CD4 receptor and the CCR5 coreceptor, inducing a series of conformational changes in Env that culminate in virus and host cell membrane fusion (Hill et al., 1997; Kwong et al., 1998; Trkola et al., 1996) . Several CCR5-binding compounds including Maraviroc, Vicriviroc, Aplaviroc, TAK-779, SCH-C and CMPD 167 antagonize this process and have a strong anti-viral activity against HIV-1 in vitro (Baba et al., 1999; Dorr et al., 2005; Strizki et al., 2001 Strizki et al., , 2005 Veazey et al., 2003; Watson et al., 2005) . Maraviroc (MVC; Pfizer) was approved by the FDA in 2007 and is being used for treating HIV-1-infected people. Vicriviroc (VVC; Schering-Plough-now Merck) and Aplaviroc (AVC; GlaxoSmithKline) were tested in clinical trials, but were not pursued because of suboptimal efficacy and liver toxicity, respectively.
HIV-1 resistance to CCR5 antagonists can occur both in vitro and in vivo (Kuhmann et al., 2004; Marozsan et al., 2005; Ogert et al., 2010; Tsibris et al., 2008) . In the most common genetic route to resistance, multiple sequence changes in V3 make the virus more dependent on the CCR5 N-terminus (NT) (Baba et al., 2007; Berro et al., 2009; Kuhmann et al., 2004; Nolan et al., 2009; Ogert et al., 2008 Ogert et al., , 2010 Tsibris et al., 2008) . A much rarer pathway involves changes in the fusion peptide (FP) of the gp41 protein (Anastassopoulou et al., 2009) . In all cases, the resistant viruses gain the ability to enter cells via the inhibitor-CCR5 complex while retaining the use of free CCR5 (Pugach et al., 2007) .
While VVC and MVC both bind to a similar hydrophobic pocket in the CCR5 transmembrane domains, they do so in subtly distinctive ways by interacting with different amino acids (Labrecque et al., 2011) . As a corollary, VVC and MVC (and other class members) may stabilize different CCR5 conformations, which could influence the escape pathway taken by the virus. Although cross-resistance is commonly observed among the CCR5 inhibitors, there are examples of compound-dependent resistance (Tilton et al., 2010; Westby et al., 2007) . Here, we investigate which sequence changes in V3 are most associated with VVC and MVC resistance, and use molecular models to assess what impact the various resistance-associated changes have on V3 structure. We found that the V3 amino acid substitutions in the VVC-and MVC-selected viruses map to different locations, involve residues with varying electrostatic charges, and have distinctive effects on how V3 interacts with CCR5 NT.
Results and discussion

MVC and VVC resistance map to different V3 amino acids
We compiled V3 sequences from viruses with proven susceptibility or resistance to MVC or VVC (Table 1) . The sequences were derived Virology 427 (2012) 158-165 from patients that failed therapy with the specified drug, or from escape viruses selected in vitro under the selection pressure of one of the compounds Kuhmann et al., 2004; Lewis et al., 2010; McNicholas et al., 2010 McNicholas et al., , 2011 Ogert et al., 2008 Ogert et al., , 2009 Ogert et al., , 2010 Pfizer, 2007; Putcharoen et al., 2011; Tilton et al., 2010; Tsibris et al., 2008; Westby et al., 2007; Yuan et al., 2011) . In total, sequences from 14 VVC-selected and 18 MVC-selected clones were compared to the inhibitor-sensitive clones from which they were derived (Table 1) . When multiple V3 sequences were available from the resistant viruses, we used only the one associated with the lowest maximum percent inhibition (MPI) value (i.e., from the most resistant clone). In cases where the sequence appears to indicate that two different resistant variants were present in the viral quasispecies, both were analyzed independently. In the original studies, four of the 14 VVC-selected viruses were tested for MVC sensitivity and found to be cross-resistant, while none of the three tested MVC-selected viruses was cross-resistant to VVC (Table 1) . However, even when cross-resistance to MVC was demonstrated, the viruses were generally more resistant to the selecting compound, VVC, as indicated by lower MPI values (Kuhmann et al., 2004; Putcharoen et al., 2011; Tsibris et al., 2008) .
We first compared the location of V3 amino acid substitutions between VVC-and MVC-selected clones, taking note only of changes that occurred more than once at the same location in each sequence dataset ( Fig. 1A ). MVC-associated changes arose only in 7 positions located in the V3 tip and stem regions, whereas VVC-associated changes were more widely distributed, involving 15 positions scattered throughout the tip, stem and base of V3 ( Fig. 1A) .
Some resistance-associated changes were predominant for one of the selecting compounds. The most frequent (6/18 sequences) MVCassociated substitution occurred at amino acid Ile-322a, which was always substituted with Val (the amino acid designated 322a is not present in HXB2 but is located between residues 322 and 323 of that virus). In contrast, changes to this residue never arose under the selection pressure of VVC (0/14 sequences, p = 0.020, one-tailed Fisher's exact test, for the comparison). Conversely, an Arg substitution at Lys-305 was frequently associated with VVC selection (in 6/14 sequences) but was seen with MVC only once (1/18 sequences, p = 0.017, one-tailed Fisher's exact test, for the comparison). A substitution at Gly-321 arose 4 times under VVC selection, in 3 cases involving a change to Glu, and was always accompanied by the to inhibitor a All sequences correspond to individual Env clones except those from the MOTIVATE trial of MVC (Lewis et al. 2010; Pfizer, 2007) , which represent the consensus of multiple clones from the same patient. b Residues highlighted in red indicate substitutions that have been confirmed to cause resistance, and in blue, substitutions that have not been verified. c In all cases, inhibitor susceptibility was determined in the U87-CD4-CCR5 cell line except for Jakobsen et al., 2011 and Tilton et al., 2010 where NP2-CD4-CCR5 cells were used. d CR = cross-resistance; Y: yes, N: No; NT: not tested. e Clade not identified; in Yuan et al., 2011 , the resistant virus was selected from a V3 loop library virus, with random mutations introduced at 10 different residues (Yusa et al., 2005) . f The selecting agent was AD101, a pre-clinical precursor of VVC with similar structural properties. g Negative MPI values indicate an enhanced replication in the presence of the selecting drug as compared to no drug.
K305R change. Comparing how frequently each V3 residue was changed in the VVC-and MVC-escape virus datasets, we found that only substitutions at I322a (for MVC escapes), or K305 and G/D321 (for VVC escapes) were statistically different between the two selecting compounds (pb 0.05, one-tailed Fisher's exact test, Table 2 ). Changes at these residues could, therefore, be signatures for MVC vs. VVC resistance. The amino acids present at V3 positions 308 and 322 vary both between and within clades ( Table 2) . Substitutions at these two locations frequently arose under the selection pressure of each compound (Fig. 1A) . For MVC-selected clones, the residue introduced at position 322 was always Asp, which is a common polymorphism at this site in subtype B viruses (Table 2) . However, no specific substitution pattern could be discerned at position 322 of VVC-selected viruses. Residue-308 is naturally highly polymorphic in clade B (Table 2) ; changes here were commonly seen in response to both VVC and MVC selection, but there was no evidence for the introduction of any specific amino acid.
To determine whether resistance-associated V3 changes occur at relatively conserved or polymorphic sites, we looked at the natural sequence variation pattern at the same sites ( Table 2) . The dataset was based on a study exploring the variation of more than 350 V3 sequences from viruses of both clades B and C (Patel et al., 2008) . We found that none of the MVC-or VVC-associated substitutions arose at the more highly conserved V3 residues, but rather at positions where various amino acids are naturally tolerated (Table 2) . Thus, the selection pressure of both CCR5 inhibitors may favor the expansion of pre-existing minor variants with a degree of natural resistance. Indeed, that process has been described previously (Kuhmann et al., 2004; Roche et al., 2011) . Alternatively, these substitutions may also arise during therapy de novo.
Structural implications of the VVC-associated resistance changes
We mapped the substitutions that arose in VVC-escape variants on the structure of a model of the V3 region in complex with a fragment of the CCR5 NT that includes residues 7-15 ( Fig. 1B) (Huang et al., 2007) . The model includes Asp-11 and the sulfated tyrosines at positions 10 and 14, the three key CCR5 residues interacting with V3 (Berro et al., 2009; Farzan et al., 1999) . The model predicts that the most commonly substituted amino acids in the V3 regions of VVC-selected viruses do not directly contact CCR5 residues Tyr-10, Asp-11 and Tyr-14. Residues 321 and 322 are often altered in the V3 regions of VVC-resistant viruses; they are predicted to contact CCR5 residues Ser-7 and Asp-8. How changes at these V3 positions may change the gp120-CCR5 interaction is discussed below. The other V3 residues that are often substituted in VVCresistant viruses are not thought to contact the CCR5 NT; several are located near the V3 tip and may modulate the interaction with ECL2, directly or otherwise.
Structural implications of the MVC-associated resistance changes
The most commonly altered residue in MVC-selected viruses, Ile-322a (found 6 times), was invariant when VVC was the selecting drug (p = 0.020, one-tailed Fisher's exact test, for the comparison). This residue contacts all three key residues in the CCR5 NT that are predicted to interact with V3, namely Asp-11, Tyr-10 and Tyr-14. The hydrophobic side chain of Ile-322a intercalates between all three CCR5 residues, making hydrophobic contacts with the aromatic rings of both Tyr residues and also with the backbone of Asp-11 (Fig. 1C) . When Val replaces Ile at position 322a, which frequently occurs under MVC selection, the loss of the methyl group is likely to alter the hydrophobic packing of these interactions and thereby modulate how V3 interacts with the CCR5 NT. A model of a MVC-resistant V3 predicted that the I322aV change disrupted a β-sheet in the stem, creating a more disordered secondary structure in this region, and that the introduced Val residue would occupy less space than the original Ile, thus reducing the interface areas between V3 and the CCR5 NT .
Substitutions at the neighboring residue 322, which contacts Ser-7 and Asp-8 of the CCR5 NT, are involved in both VVC-and MVCresistance, but different amino acids are introduced in each case. Under VVC selection, the change is usually from a charged amino acid (most commonly Asp) to another charged or neutral one, while with MVC there appears to be a selective preference for Asp. It is unclear how these changes affect V3-CCR5 interactions (but see below). Other frequently changed residues located more towards the tip of V3 do not contact the CCR5 NT directly. b Only substitutions that occur more than once at the same V3 position within the same dataset are displayed; all sequences in Table 1 were included in the analysis. c Differences in substitution frequency of p b 0.05 based on a Fisher's exact test were considered statistically significant and are shown in italics.
VVC-resistance, but not MVC-resistance, involves a redistribution of V3 charge
The V3 region of CCR5-using viruses has a net positive charge (median of 3) (Clevestig et al., 2006) , and how V3 interacts with CCR5 is strongly influenced by its electrostatic potential (Cormier et al., 2001) . We therefore studied the electrostatic properties of the V3 residues that change in response to MVC or VVC selection. Our emphasis was on neutral-to-charged residue changes, and vice versa, and substitutions that introduced a different charged residue at the same position ( Fig. 2A) .
Viruses selected by VVC contained several V3 substitutions to or from a charged residue (median = 2), while their MVC-selected counterparts did not (median = 0) ( Fig. 2A) . The difference was highly significant (p b 0.0001, one-tailed Mann-Whitney U test), even when we normalized to the total number of changes (p b 0.0001). The latter number (i.e. total number of substitutions per V3 sequence) was slightly higher for VVC because the sequences were usually derived from a later time point during therapy (data not shown). The net charge of MVC-selected V3 regions did not change (median = 0), but for VVC there was a non-significant trend towards a decrease in positive charge (median = − 1) ( Fig. 2B) .
To see how the charge changes that are selected during VVC-therapy might modulate how V3 interacts with the CCR5 NT, we studied the electrostatic surface potential of one VVC-sensitive/resistant V3 pair that contains three frequently occurring changes: K305R (observed 6 times, overall), S/G306P (3 times) and G321E (3 times) (Tsibris et al., 2008) . The G321E change was always present together with K305R, suggesting an evolutionary linkage. That this combination was never found in MVC-selected viruses implies specificity for VVC-resistance. The parental, VVC-sensitive sequence forms a large, positive surface containing a cavity that accommodates the sulfated Tyr-14 residue of CCR5, while the sulfated Tyr-10 residue binds at the edge of the positive surface (Fig.2C, upper panels) . The VVC-selected V3 changes did not affect the electrostatic surface potential of the binding sites for Tyr-10 and Tyr-14 ( Fig.2C, lower panels) . However, positive charge was lost from regions near position 305 located towards the middle of V3. The cause was not the K305R substitution, but rather that the glutamic Fig. 2 . VVC-resistance, but not MVC-resistance involves a redistribution of V3 charge. A. MVC-and VVC-associated substitutions involving a charged residue are displayed as the total number of charged changes per V3 pair. ***, p b 0.0001 (one-tailed Mann-Whitney U test). B. A comparison of the net charge of the V3 sequences from MVC-or VVCselected viruses. N.S., non-significant (p > 0.05, one-tailed Mann-Whitney U test). C. Electrostatic surface potential of a representative VVC-sensitive/resistant V3 pair (Tsibris et al., 2008) . Sensitive virus, upper panels; resistant virus, lower panels. The right panels are rotated to allow CCR5 residues Tyr-14 and Asp-11 to be viewed. acid introduced by the accompanying G321E change neutralizes the positive charge of Arg-305 via formation of a salt bridge. We have previously suggested that the K305R plus G321E combination may contribute to V3 stability by favoring a β-sheet structure through formation of an inter-strand salt bridge (Berro et al., 2009 ). Overall, it seems possible that this pair of substitutions affects how V3 interacts with Asp-11 on the CCR5 NT, both by stabilizing a particular β-sheet conformation and by changing the electrostatic surface potential. Whatever the underlying mechanism, the outcome may be a reduced or lost interaction between V3-residue 305 and Asp-11 on CCR5.
In general, to acquire the ability to bind the inhibitor-CCR5 complex and become resistant, gp120 may need to sacrifice some contacts that are normally involved in its interaction with free CCR5. That loss may have adverse consequences for the efficiency of CCR5 binding and hence virus entry in the absence of the selecting compound, i.e., via free CCR5. Thus, some resistant viruses selected during VVC-therapy in vivo have delayed entry kinetics in the absence of VVC, indicative of a fitness loss, but the addition of the inhibitor restored the rate of entry to a level comparable to wild type viruses (Putcharoen et al., 2011; Tsibris et al., 2008) . A similar loss of fitness that was also reversed upon addition of the inhibitor was observed in viruses selected for VVC-resistance in vitro (Anastassopoulou et al., 2007) . When the inhibitor is present, the weakening of the interaction between V3 and the CCR5 NT may be compensated for by the acquisition of additional binding sites involving the NT or other regions of the inhibitor-CCR5 complex. Further evidence that the resistance-associated V3 changes affect the overall geometry of the Env complex is that resistant viruses become more sensitive to neutralizing antibodies against V3 (Berro et al., 2009; Laakso et al., 2007; Nolan et al., 2009) .
Conclusion
The MVC-and VVC-selected sequence changes map to different amino acids in V3 but in both cases they generally arise at naturally polymorphic sites. The two sets of changes are each likely to modulate how V3 interacts with the CCR5 NT, but in different ways. Why do MVC and VVC drive different patterns of V3 changes? The two compounds presumably alter the overall conformation of CCR5 in subtly distinctive ways, via interactions with different residues in the transmembrane cavity where they each bind, as judged by the ability of these compounds to affect the binding of various conformation-dependent monoclonal antibodies to CCR5 (Tilton et al., 2010) . In both cases, the geometry of the CCR5 NT and ECL2 regions is modified so as to alter the multi-point binding site that HIV-1 normally recognizes. The virus counters by introducing V3 sequence changes that allow it to still interact with the CCR5 NT, but in a different way. However, exactly what V3 changes allow this interaction must depend on the precise orientation of the NT on the inhibitor-CCR5 complex, which must differ, to at least some extent, between MVC and VVC. Understanding the details would require detailed structural information on CCR5 (free and ligated by each inhibitor) and the native Env trimer, which is presently unavailable. That kind of structural information would also help us understand why VVC-selected variants tend to be cross-resistant to MVC, whereas MVC-selected viruses sometimes remain sensitive to VVC and other similar inhibitors.
Finally, this is the first comprehensive study comparing the pattern of sequence changes induced by VVC and MVC resistance. Although the total number of sequences analyzed was limited by the extent of published data, it is clear that the two drugs drive different patterns of V3 changes. Because the V3 is highly variable it lends itself to a high level of baseline variability. Therefore, the power of our analysis could be enhanced in the future by a larger data set and a clade-specific sequence analysis. Our conclusion that different small molecule CCR5 inhibitors drive different resistance mechanisms should be clinically relevant. Knowing that the various drugs might lead to different mechanisms of resistance should assist the design and development of the next generation CCR5 antagonists and anticipate the viral escape pathways.
Materials and methods
Statistical analysis
The V3 sequence charge redistribution was analyzed using the Mann-Whitney U test in GraphPad Prism (GraphPad, San Diego, CA). The number of changes involving charge per V3 sequence was determined for each selecting compound and then compared between the two datasets. Changes to or from a charged residue were counted.
To compare whether substitutions at certain V3 residues were associated with VVC or MVC-selection pressure, we calculated the frequency of substitution of each V3 residue in each dataset (VVC vs. MVC). Thus, we divided the number of substitutions at a certain position by the total number of sequences in each dataset. We then compared the substitution frequency between the two datasets to determine whether changes at certain V3 positions were associated with resistance to one inhibitor vs. the other by performing a Fisher's exact test. p-Values b 0.05 were considered statistically significant, and hence indicative of V3 positions that are more likely to be changed as a response to one inhibitor vs. the other.
Structural analysis
The structure of a V3-containing gp120 in complex with CD4 and the sulfated 412 d antibody (Protein Databank (pdb) accession code: 2QAD) was used for the structural analyses, in combination with a model of a docked structure of the CCR5 NT (Huang et al., 2007) ; http://www.niaid.nih.gov/labsandresources/labs/aboutlabs/vrc/structu ralbiologylaboratory/Pages/kwong.aspx). Substitutions and electrostatic surface potentials were generated using Pymol (www.pymol.org) and figures were prepared using Pymol.
